Ann: Alterity to Deliver Multiple Presentations at MDS Congress, page-34

As we patiently wait for our updated 202 interim results, couple other reports from MDS conference quite interesting.

Abstract 1 of brain de-ironization in MSA patient using deferiprone nasal spray. Looks to have impressive clinical results in this one MSA patient. Adds more evidence of iron removal benefit in MSA.

https://www.mdsabstracts.org/abstract/brain-de-ironization-with-nasal-spray-of-iron-chelator-in-treatment-of-multiple-system-atrophy-a-case-trial/




Also LBA-12, Abbvie’s Tavapadon showing improvements for PD patients. Abbvie paid $8.7 bn US acquiring Cerevel, with tevapadon closest to market, also gained hyped up schizophrenia emraclidine in ph2, plus some others. Shows pharma are on the look out for big purchases.



https://www.mdscongress.org/IC24-lbas
https://www.biopharminternational.com/view/abbvie-completes-8-7-billion-acquisition-of-cerevel-therapeutics-to-boost-neurological-pipeline